New Zealand - English - Medsafe (Medicines Safety Authority)

biomed limited - arginine hydrochloride 5% - solution for infusion - 5 % - active: arginine hydrochloride 5% excipient: purified water - arginine hydrochloride 5% is indicated for the evaluation of pituitary growth hormone reserve.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - l-arginine monohydrochloride; l-lysine monohydrochloride - infusion - 25mg/1ml ; 25mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - arginine hydrochloride, quantity: 600 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - indications as at 01 jan 1991 : arginine stimulates the release of growth hormone by the pituitary gland and may be used instead of , or in addition to, other tests such as insulin-induced hypoglycaemia, for the evaluation of growth disorders; false positive and false negative results are relatively common and evaluation therefore should not be made on the basis of a single arginine test. arginine is used as an acidifying agent in severe metabolic alkalosis. arginine is used in some conditions accompanied by hyperammonaemia stemming from inborn errors of the urea cycle, particularly where there is a severe deficiency of ornithine carbamoyl transferase or carbamoyl phosphate synthetase where respiratory alkalosis is present.

Australia - English - Department of Health (Therapeutic Goods Administration)

australian naturalcare products pty ltd - lysine hydrochloride -

European Union - English - EMA (European Medicines Agency)

advanced accelerator applications - l-arginine hydrochloride, l-lysine hydrochloride - radiation injuries - detoxifying agents for antineoplastic treatment - lysakare is indicated for reduction of renal radiation exposure during peptide-receptor radionuclide therapy (prrt) with lutetium (177lu) oxodotreotide in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril arginine, quantity: 10 mg; amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg) - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica - perindopril arginine and amlodipine combination tablet is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg); perindopril arginine, quantity: 5 mg - tablet - excipient ingredients: colloidal anhydrous silica; croscarmellose sodium; microcrystalline cellulose; magnesium stearate - perindopril arginine and amlodipine combination tablet is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril arginine, quantity: 10 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose - perindopril arginine and amlodipine combination tablet is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); perindopril arginine, quantity: 5 mg - tablet - excipient ingredients: colloidal anhydrous silica; croscarmellose sodium; microcrystalline cellulose; magnesium stearate - perindopril arginine and amlodipine combination tablet is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - amlodipine besilate, quantity: 13.87 mg; perindopril arginine, quantity: 10 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; lactose monohydrate; magnesium stearate - apx-perindopril arginine/ amlodipine is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.